Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 2,543
Change Today +40.00 / 1.60%
Volume 24.7K
As of 10:24 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

compugen ltd (CGEN) Snapshot

Open
$2,503
Previous Close
$2,503
Day High
$2,554
Day Low
$2,503
52 Week High
01/12/15 - $3,770
52 Week Low
11/17/14 - $2,454
Market Cap
1.2B
Average Volume 10 Days
51.5K
EPS TTM
$-0.82
Shares Outstanding
48.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COMPUGEN LTD (CGEN)

compugen ltd (CGEN) Related Businessweek News

No Related Businessweek News Found

compugen ltd (CGEN) Details

Compugen Ltd., a drug discovery company, engages in the research, development, and commercialization of therapeutic and product candidates primarily in the United States, Europe, and Israel. It primarily focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins to address the unmet needs in the fields of oncology and immunology. The company’s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 for the treatment of a range of diseases including cancer, autoimmune and infectious diseases, blood-related disorders, and others. Its monoclonal antibody therapy product candidates comprise CGEN-15001T, CGEN-15022, CGEN-15049, CGEN-15027, CGEN-15092, and CGEN-15052. The company was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

83 Employees
Last Reported Date: 03/12/15
Founded in 1993

compugen ltd (CGEN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $295.8K
Vice President of Antibody Research & Develop...
Total Annual Compensation: $274.8K
Vice President of Research & Discovery
Total Annual Compensation: $193.6K
Vice President of R&D Planning and Control
Total Annual Compensation: $154.1K
Compensation as of Fiscal Year 2014.

compugen ltd (CGEN) Key Developments

Compugen Ltd. and Kanit Ha’Shalom Investments Ltd. Enter into Lease Agreement; Announces Relocation of Headquarters

On March 19, 2015, Compugen Ltd. and Kanit Ha’Shalom Investments Ltd. (Azrieli) entered into a Lease Agreement. Under the terms of the Agreement, Compugen will lease approximately 34,000 square feet of office and laboratory space in the Azrieli Holon Business Center which is located in Holon, Israel. The Agreement has a term of ten years, and the annual rent and asset management fees payments will be approximately $800,000. The company also announced the planned relocation by year-end of its Tel-Aviv headquarters, along with its Israeli research and discovery operations, to substantially larger facilities. The new facilities, now being prepared according to Compugen’s specifications, will support the ongoing growth of the company and the further advancement of its novel immune checkpoint programs for cancer immunotherapy. The new facilities will be located in the Azrieli Holon Business Center about 12 miles south of Compugen’s current location and will double the available space for the company’s corporate offices and labs.

Felix Karim Joins Compugen as Vice President Corporate & Business Development, Effective March 2, 2015

Compugen Ltd. announced the appointment of Dr. Felix Karim as Vice President Corporate & Business Development, effective March 2, 2015. Dr. Karim, who will be based at Compugen's South San Francisco facilities, will report to Dr. Anat Cohen-Dayag, Compugen's President and Chief Executive Officer, and will have direct responsibility for the company's business development strategy and its execution. Dr. Karim has significant experience in the biopharmaceutical industry and has held various executive roles in business development and R&D management. His most recent position prior to joining Compugen was Head of External R&D (licensing) for the San Francisco region at Amgen.

Compugen Ltd. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Compugen Ltd. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss for of $1.5 million, or $0.03 per basic and diluted share, compared with a net loss of $2.9 million, or $0.09 per diluted share, in the comparable period of 2013. The company posted revenues for the fourth quarter of 2014 of $6.6 million compared with $1.8 million in the comparable period of 2013. The increase in revenues is attributable to the milestone payments in the amount of $7.2 million and the relevant portion of the non-refundable upfront payment, both relating to the August 2013 collaboration and license agreement with Bayer HealthCare. Operating loss was $1.12 million against $3.96 million a year ago. Net loss before taxes was $1.18 million against $2.58 million a year ago. For the year, the company reported revenues of $12.37 million against $3.5 million a year ago. Operating loss was $12.34 million against $17.04 million a year ago. Net loss before taxes was $10.73 million against $13.58 million a year ago. Net loss was $11.09 million or $0.23 basic and diluted per share against $14.08 million or $0.36 basic and diluted per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGEN:IT 2,543.00 +40.00

CGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CGEN.
View Industry Companies
 

Industry Analysis

CGEN

Industry Average

Valuation CGEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COMPUGEN LTD, please visit www.cgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.